Article | Published:

ClC-3 promotes angiotensin II-induced reactive oxygen species production in endothelial cells by facilitating Nox2 NADPH oxidase complex formation

Acta Pharmacologica Sinica (2018) | Download Citation

Subjects

Abstract

Recent evidence suggests that ClC-3, a member of the ClC family of Cl channels or Cl/H+ antiporters, plays a critical role in NADPH oxidase-derived reactive oxygen species (ROS) generation. However, the underling mechanisms remain unclear. In this study we investigated the effects and mechanisms of ClC-3 on NADPH oxidase activation and ROS generation in endothelial cells. Treatment with angiotensin II (Ang II, 1 μmol/L) significantly elevated ClC-3 expression in cultured human umbilical vein endothelial cells (HUVECs). Furthermore, Ang II treatment increased ROS production and NADPH oxidase activity, an effect that could be significantly inhibited by knockdown of ClC-3, and further enhanced by overexpression of ClC-3. SA-β-galactosidase staining showed that ClC-3 silencing abolished Ang II-induced HUVEC senescence, whereas ClC-3 overexpression caused the opposite effects. We further showed that Ang II treatment increased the translocation of p47phox and p67phox from the cytosol to membrane, accompanied by elevated Nox2 and p22phox expression, which was significantly attenuated by knockdown of ClC-3 and potentiated by overexpression of ClC-3. Moreover, overexpression of ClC-3 increased Ang II-induced phosphorylation of p47phox and p38 MAPK in HUVECs. Pretreatment with a p38 inhibitor SB203580 abolished ClC-3 overexpression-induced increase in p47phox phosphorylation, as well as NADPH oxidase activity and ROS generation. Our results demonstrate that ClC-3 acts as a positive regulator of Ang II-induced NADPH oxidase activation and ROS production in endothelial cells, possibly via promoting both Nox2/p22phox expression and p38 MAPK-dependent p47phox/p67phox membrane translocation, then increasing Nox2 NADPH oxidase complex formation.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from $8.99

All prices are NET prices.

References

  1. 1.

    Lambeth JD. Nox/Duox family of nicotinamide adenine dinucleotide (phosphate) oxidases. Curr Opin Hematol. 2002;9:11–7.

  2. 2.

    Lassegue B, Clempus RE, Vascular. NAD(P)Hoxidases: specific features, expression, and regulation. Am J Physiol. 2003;285:R277–97.

  3. 3.

    Duan D, Winter C, Cowley S, Hume JR, Horowitz B. Molecular identification of a volume-regulated chloride channel. Nature. 1997;390:417–21.

  4. 4.

    Jentsch TJ. Chloride and the endosomal-lysosomal pathway: emerging roles of CLC chloride transporters. J Physiol (Lond). 2007;578(pt 3):633–40.

  5. 5.

    Duran C, Thompson CH, Xiao Q, Hartzell HC. Chloride channels: often enigmatic, rarely predictable. Annu Rev Physiol. 2010;72:95–121.

  6. 6.

    Guan YY, Wang GL, Zhou JG. The ClC-3 Cl- channel in cell volume regulation, proliferation and apoptosis in vascular smooth muscle cells. Trends Pharmacol Sci. 2006;27:290–6.

  7. 7.

    Chu X, Filali M, Stanic B, Takapoo M, Sheehan A, Bhalla R, et al. A critical role for chloride channel-3 (CIC-3) in smooth muscle cell activation and neointima formation. Arterioscler Thromb Vasc Biol. 2011;31:345–51.

  8. 8.

    Tao J, Liu CZ, Yang J, Xie ZZ, Ma MM, Li XY, et al. ClC-3 deficiency prevents atherosclerotic lesion development in ApoE−/− mice. J Mol Cell Cardiol. 2015;87:237–47.

  9. 9.

    Zheng LY, Li L, Ma MM, Liu Y, Wang GL, Tang YB, et al. Deficiency of volume-regulated ClC-3 chloride channel attenuates cerebrovascular remodelling in DOCA-salt hypertension. Cardiovasc Res. 2013;100:134–42.

  10. 10.

    Moreland J, Davis A, Bailey G, Nauseef W, Lamb F. Anion channels, including ClC-3, are required for normal neutrophil oxidative function, phagocytosis, and transendothelial migration. J Biol Chem. 2006;281:12277–88.

  11. 11.

    Miller F, Filali M, Huss G, Stanic B, Chamseddine A, Barna T, et al. Cytokine activation of nuclear factor B in vascular smooth muscle cells requires signaling endosomes containing Nox1 and ClC-3. Circ Res. 2007;101:663–71.

  12. 12.

    Gaurav R, Bewtra AK, Agrawal DK. Chloride channel 3 channels in the activation and migration of human blood eosinophils in allergic asthma. Am J Respir Cell Mol Biol. 2015;53:235–45.

  13. 13.

    Liu J, Zhang FF, Li L, Yang J, Liu J, Guan YY, et al. ClC-3 deficiency prevents apoptosis induced by angiotensin II in endothelial progenitor cells via inhibition of NADPH oxidase. Apoptosis. 2013;18:1262–73.

  14. 14.

    Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87:245–313.

  15. 15.

    Yang H, Huang LY, Zeng DY, Huang EW, Liang SJ, Tang YB, et al. Decrease of intracellular chloride concentration promotes endothelial cell inflammation by activating nuclear factor-κB pathway. Hypertension. 2012;60:1287–93.

  16. 16.

    Dikalov SI, Nazarewicz RR, Bikineyeva A, Hilenski L, Lassègue B, Griendling KK, et al. Nox2-induced production of mitochondrial superoxide in angiotensin II-mediated endothelial oxidative stress and hypertension. Antioxid Redox Signal. 2014;20:281–94.

  17. 17.

    Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol. 2004;4:181–9.

  18. 18.

    Groemping Y, Lapouge K, Smerdon SJ, Rittinger K. Molecular basis of phosphorylation-induced activation of the NADPH oxidase. Cell. 2003;113:343–55.

  19. 19.

    Parinandi NL, Kleinberg MA, Usatyuk PV, Cummings RJ, Pennathur A, Cardounel AJ, et al. Hyperoxia-induced NAD(P)H oxidase activation and regulation by MAP kinases in human lung endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2003;284:L26–38.

  20. 20.

    Lal AS, Clifton AD, Rouse J, Segal AW, Cohen P. Activation of the neutrophil NADPH oxidase is inhibited by SB 203580, a specific inhibitor of SAPK2/p38. Biochem Biophys Res Commun. 1999;259:465–70.

  21. 21.

    Lassegue B, Griendling KK. Reactive oxygen species in hypertension: an update. Am J Hypertens. 2004;17:852–60.

  22. 22.

    Li JM, Shah AM. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol. 2004;287:R1014–30.

  23. 23.

    Schulz E, Gori T, Münzel T. Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res. 2011;34:665–73.

  24. 24.

    Murphy R, DeCoursey T. Charge compensation during the phagocyte respiratory burst. Biochim Biophys Acta. 2006;1757:996–1011.

  25. 25.

    Lassegue B. How does the chloride/proton antiporter ClC-3 control NADPH oxidase? Circ Res. 2007;101:648–50.

  26. 26.

    Schuhmacher S, Foretz M, Knorr M, Jansen T, Hortmann M, Wenzel P, et al. α1AMP-activated protein kinase preserves endothelial function during chronic angiotensin II treatment by limiting Nox2 upregulation. Arterioscler Thromb Vasc Biol. 2011;31:560–6.

  27. 27.

    Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res. 2002;90:E58–65.

  28. 28.

    Fisher AB. Redox signaling across cell membranes. Antioxid Redox Signal. 2009;11:1349–56.

  29. 29.

    Liu YJ, Wang XG, Tang YB, Chen JH, Lv XF, Zhou JG, et al. Simvastatin ameliorates rat cerebrovascular remodeling during hypertension via inhibition of volume-regulated chloride channel. Hypertension. 2010;56:445–52.

  30. 30.

    Huang YY, Huang XQ, Zhao LY, Sun FY, Chen WL, Du JY, et al. ClC-3 deficiency protects preadipocytes against apoptosis induced by palmitate in vitro and in type 2 diabetes mice. Apoptosis. 2014;19:1559–70.

Download references

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 81373401 and 81573422); Natural Science Foundation of Guangdong Province, China (No. S2013010016611); and the Fundamental Research Funds for the Central Universities (No. 2015ykzd01).

Author information

Author notes

  1. These authors contributed equally: Guo-zheng Liang, Li-min Cheng.

Affiliations

  1. Department of Pharmacology, Cardiac & Cerebral Vascular Research Center, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, 510080, China

    • Guo-zheng Liang
    • , Li-min Cheng
    • , Xing-feng Chen
    • , Yue-jiao Li
    • , Xiao-long Li
    • , Yong-yuan Guan
    •  & Yan-hua Du

Authors

  1. Search for Guo-zheng Liang in:

  2. Search for Li-min Cheng in:

  3. Search for Xing-feng Chen in:

  4. Search for Yue-jiao Li in:

  5. Search for Xiao-long Li in:

  6. Search for Yong-yuan Guan in:

  7. Search for Yan-hua Du in:

Contributions

Y-hD and G-zL designed the study and drafted the manuscript; G-zL and L-mC performed the experiments; Y-yG assisted with the data analyses and discussion; other colleagues assisted with the experiments and data collection.

Competing interests

The authors declare no competing interests.

Corresponding author

Correspondence to Yan-hua Du.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/s41401-018-0072-0